Oryzon Genomics Valuation
Is ORY N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ORY N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ORY N's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ORY N's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ORY N?
Key metric: As ORY N is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ORY N's PS Ratio? | |
|---|---|
| PS Ratio | 7.8x |
| Sales | US$17.06m |
| Market Cap | US$133.89m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.9x |
| Enterprise Value/EBITDA | -23.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ORY N's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.5x | ||
A092040 Amicogen | 1.3x | n/a | ₩203.1b |
IPH Innate Pharma | 3.7x | 26.2% | €124.0m |
PLX Protalix BioTherapeutics | 2.7x | 58.9% | US$124.4m |
1783 Maxigen Biotech | 6.3x | n/a | NT$3.9b |
ORY N Oryzon Genomics | 7.8x | 59.1% | Mex$124.4m |
Price-To-Sales vs Peers: ORY N is good value based on its Price-To-Sales Ratio (7.8x) compared to the peer average (8.1x).
Price to Sales Ratio vs Industry
How does ORY N's PS Ratio compare vs other companies in the Global Biotechs Industry?
| 278 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 278 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: ORY N is good value based on its Price-To-Sales Ratio (7.8x) compared to the Global Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is ORY N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 7.8x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ORY N's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
-11.8%
1Y
12.0%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a